V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

LeMaitre Vascular Executive Compensation (FY25)

LMAT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
George LeMaitre
Latest say-on-pay support
=
June 2, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The LeMaitre Vascular brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 5, 2026
4 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
LeMaitre Vascular brief$1,500Get the executive brief
Velarion Member, one year
307 figures on this page: 305 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — George LeMaitre: $3,235,558 → $3,780,990 (16.9% higher)
Say-on-pay support: 95.4% → 96.0% (0.6 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is LeMaitre Vascular's chief executive and what were they paid?
George LeMaitre was paid $3,780,990 in total compensation as Chairman and Chief Executive Officer for fiscal 2025. Compared with the $3,235,558 reported for fiscal 2024, LeMaitre's total was 16.9% higher.
What was LeMaitre Vascular's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 96.0% of votes cast for or against in favor at the meeting held June 2, 2026.
Which companies are in LeMaitre Vascular's peer group?
The disclosed peer group names Angiodynamics, Inc., Anika Therapeutics, Inc., Artivion, Inc., Atricure, Inc. and Atrion Corporation, among others.
What is LeMaitre Vascular's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 43:1, against median employee compensation of $88,782.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
George LeMaitre
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
David Roberts
President
◇—◇◇◇—◇◇
Joseph Pellegrino
Chief Financial Officer
◇—◇◇◇——◇
Trent Kamke
Senior Vice President, Operations
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
George LeMaitre
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
David Roberts
President
◇—◇◇◇—◇◇
Joseph Pellegrino
Former Chief Financial Officer
◇◇◇◇◇——◇
Trent Kamke
Senior Vice President, Operations
◇◇◇◇◇—◇— not reconciled
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
George LeMaitre
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
Joseph Pellegrino
Former Chief Financial Officer
◇—◇◇◇——◇
David Roberts
President
◇◇◇◇◇—◇◇
Trent Kamke
Senior Vice President, Operations
◇◇◇◇◇—◇— not reconciled
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
George LeMaitre
Chairman and Chief Executive Officer
◇—◇◇◇—◇◇
David Roberts
President
◇◇◇◇◇—◇◇
Dorian LeBlanc
Chief Financial Officer
◇◇◇◇◇—◇◇
Trent Kamke
Senior Vice President, Operations
◇◇◇◇◇—◇— not reconciled
Joseph Pellegrino
Former Chief Financial Officer
Departed during or after this year
◇◇————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David B. RobertsPSU◇◇◇—◇—◇
David B. RobertsOPTION◇——◇—◇◇
Dorian P. LeBlancPSU◇◇◇—◇—◇
Dorian P. LeBlancOPTION◇——◇—◇◇
George W. LeMaitrePSU◇◇◇—◇—◇
George W. LeMaitreOPTION◇——◇—◇◇
Joseph P. Pellegrino JrPSU◇◇◇—◇—◇
Joseph P. Pellegrino JrOPTION◇——◇—◇◇
Trent G. KamkeOPTION◇——◇—◇◇
Trent G. KamkePSU◇◇◇—◇—◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
David RobertsOption◇—◇—
RSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
Option◇—◇—
George LeMaitrePSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Joseph PellegrinoRSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Trent KamkeOption◇—◇—
Option◇—◇—
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Dorian LeBlancOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Dorian LeBlanc
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance cash amount◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lawrence J. Jasinski
◇◇◇———◇
John J. O'Connor
◇◇◇———◇
John A. Roush
◇◇◇———◇
Bridget A. Ross
◇◇◇———◇
Martha Shadan
◇◇◇———◇
Joseph P. Pellegrino Jr
◇◇◇———◇
George W. LeMaitre served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options, Performance Stock, RSUs.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
  • Angiodynamics, Inc. ANGO
  • Anika Therapeutics, Inc. ANIK
  • Artivion, Inc. AORT
  • Atricure, Inc. ATRC
  • Atrion Corporation ATRI
  • AxoGen, Inc. AXGN
  • Aziyo Biologics, Inc. ELUT
  • Cardiovascular Systems, Inc. TCMD
  • ConforMIS, Inc. symbol not shown
  • Merit Medical Systems, Inc. MMSI
  • Orthofix Medical Inc. OFIX
  • Surmodics, Inc. SRDX
  • TransMedics Group, Inc. TMDX
  • Vapotherm, Inc. VAPO

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 2, 2026=◇◇◇
2024June 2, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- George LeMaitre (Chairman and Chief Executive Officer), FY2025 total compensation $3,780,990 (base salary $806,347) [exec_comp, SEC accession 0001193125-26-153877, filed 2026-04-14]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when LeMaitre Vascular files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact LeMaitre Vascular disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where LeMaitre Vascular sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether LeMaitre Vascular's disclosed peer group is defensible, who names LeMaitre Vascular back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
307 figures on this page: 305 cited to the filing that reported them, 2 calculated from figures it prints.
305 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001193125-26-257978
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-153877
    Compensation Discussion and Analysis · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Pay Ratio Disclosure
  3. 0001437749-25-019314
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001437749-23-010217
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “LeMaitre Vascular executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LMAT (accessed 2026).
Short form: data: Velarion

The LeMaitre Vascular brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about LeMaitre Vascular and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers LeMaitre Vascular discloses

The companies named in LMAT's own disclosed peer group.

Angiodynamics, Inc.Anika Therapeutics, Inc.Artivion, Inc.Atricure, Inc.Atrion CorporationAxoGen, Inc.Aziyo Biologics, Inc.Cardiovascular Systems, Inc.Merit Medical Systems, Inc.Orthofix Medical Inc.Surmodics, Inc.TransMedics Group, Inc.Vapotherm, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy